FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2026-12-23 | — | Multiple Myeloma &ndash | BLA | 83% |
PoA = estimated probability of approval from published base rates and live data. See the full PDUFA calendar →
| Drug | Indication | Phase | Status |
|---|---|---|---|
| Biktarvy Pill | Hiv | NA | WITHDRAWN |
| TL+D antiretroviral | HIV | NA | COMPLETED |
| 3rd ARV Agent | HIV-1-infection | PHASE4 | RECRUITING |
| ATV | HIV-1-infection | PHASE4 | RECRUITING |
| B/F/TAF (High Dose TOS) | HIV-1-infection | PHASE4 | RECRUITING |
| B/F/TAF (High Dose) | HIV-1-infection | PHASE4 | RECRUITING |
| B/F/TAF (Low Dose TOS) | HIV-1-infection | PHASE4 | RECRUITING |
| B/F/TAF (Low Dose) | HIV-1-infection | PHASE4 | RECRUITING |
| B/F/TAF (Lowest Dose TOS) | HIV-1-infection | PHASE4 | RECRUITING |
| Bictegravir, emtricitabine, and tenofovi | HIV -1 Infection | PHASE4 | RECRUITING |
GILD holds $5.4B in cash and its operations are currently cash-flow neutral or positive. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for GILD free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-08-11 | Cain Wettan Keeley M |
Purchase | $0 |
| 2026-08-11 | Cain Wettan Keeley M |
Sale | $1.1M |
| 2026-08-11 | Cain Wettan Keeley M |
Sale | $0 |
| 2026-08-04 | O'Day Daniel Patrick |
Sale | $77.9M |
| 2026-08-04 | O'Day Daniel Patrick |
Sale | $77.5M |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for GILD and 2 more tickers of your choice.
Create Free Account →